COVID-19 Vaccines Considered Safe and Effective in NAFLD Patients, Study Reveals

A recent study revealed that vaccination against SARS-CoV-2 does not seem to come with significant safety concerns in patients with non-alcoholic fatty liver disease (NAFLD). At the same time, vaccines can also elicit a robust neutralizing antibody response.

Photo: COVID-19 Vaccine | InStyleHealth


Research involved 381 NAFLD patients with an average age 39 years old, of which 47% were men who never had the novel coronavirus disease (COVID-19). All participants received two doses of an inactivated virus vaccine, 14 days after which blood samples were collected. The neutralizing antibodies were detected using magnetic particle chemiluminescence assays. Primary safety outcome of interest was the occurrence of the adverse events within 7 days after each injection.

In general, 95 patients saw adverse reactions within 7 days after each injection, while 112 patients had adverse reactions within 28 days. Most common side effects were injection site pain (18.4%), muscle pain (5.5%), headache (5.2%), and fatigue (4.7%).

The reported adverse events were mild and self-limiting; there were no grade 3 reactions recorded.

Regarding immunogenicity, neutralizing antibodies were first detected after an average of 39 days. Almost all (95%) of the participants vaccinated showed neutralizing antibodies, with an average titre of 32.

Researchers said that a larger prospective follow-up study for robust evidence of efficacy is needed. In conclusion, the inactivated COVID-19 vaccine appears to be safe with good immunogenicity in patients with NAFLD.

 

Source: J Hepatol 2021;doi:10.1016/j.jhep.2021.04.026

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post